Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00928837 · ClinicalTrials.gov registry record · NA
Study of Flavocoxid (Limbrel) Versus Naproxen in Subjects With Moderate-Severe Osteoarthritis of the Knee
A NA study, sponsored by Primus Pharmaceuticals.
- Completed
- Registry status
- NA
- Development phase
- 350
- Enrollment target
NCT00928837 is a NA study that has completed, run by Primus Pharmaceuticals. The registered enrollment target is 350 participants.
The verdict
NCT00928837, a NA study, has completed, sponsored by Primus Pharmaceuticals.
- COMPLETED
- Registry status
- NA
- Development phase
- 350 participants
- Enrollment target
Study Summary
The purpose of the study is to compare the efficacy and safety of flavocoxid (Limbrel) with Naproxen and placebo in OA of the knee.
Interventions
- OTHER Placebo
- DRUG Naproxen
- DIETARY_SUPPLEMENT Flavocoxid 500 mg
- OTHER flavocoxid 250 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2006-03 |
| Est. Completion | 2007-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00928837
The ClinicalTrials.gov registry entry for NCT00928837 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Primus Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00928837 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00928837 about?
NCT00928837 is a clinical study titled "Study of Flavocoxid (Limbrel) Versus Naproxen in Subjects With Moderate-Severe Osteoarthritis of the Knee". The purpose of the study is to compare the efficacy and safety of flavocoxid (Limbrel) with Naproxen and placebo in OA of the knee.
What is the current status of trial NCT00928837?
This trial is currently completed. It is a NA study. The enrollment target is 350 participants. The study started on 2006-03. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00928837?
The interventions under investigation include: Placebo (OTHER), Naproxen (DRUG), Flavocoxid 500 mg (DIETARY_SUPPLEMENT), flavocoxid 250 mg (OTHER).
Who is sponsoring clinical trial NCT00928837?
This trial is sponsored by Primus Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.